Abstract
Optimizing multivalency: Clusters of Man9 glycans, which are recognized by broadly neutralizing anti‐HIV antibody 2G12, have potential as HIV vaccines. However, optimal recognition by 2G12 requires optimum clustering of glycans. Using the recently described SELMA technique (SELection with Modified Aptamers), Man9 clusters have been developed, in which glycans are supported by DNA sequences selected from among 2×1013 variants (see scheme).
